ReviewRadiology and oncology2025
Pulsed field ablation in medicine: irreversible electroporation and electropermeabilization theory and applications.
Review in Radiology and oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Endoluminal Catheter Pulsed Field Ablation for the Treatment of Atherosclerotic Vascular Disease.Annals of biomedical engineering · 2026Article
- Localized delivery of coding nucleic acids into adherent cells by in situ electroporation: integrated impedance-based monitoring allows for loss-of-function or gain-of-function screening.Scientific reports · 2026Article
- Irreversible electroporation in focal therapy for prostate cancer: current status and future directions.Prostate international · 2026Review
- A critical review of microfluidic electroporation for therapeutic cell engineering.Cell reports. Physical science · 2026Article
- The role of bronchoscopic cryoimmunotherapy in non-small cell lung cancer: current evidence and future perspectives.Immunotherapy · 2026Review
- High-intensity irreversible electroporation targeting intracellular structures enhance tumor ablation in lung cancer models.PloS one · 2026Article
- Non-thermal venous endothelial injury by microsecond irreversible electroporation: mechanisms of apoptosis, oxidative stress, and vascular closure initiation.Frontiers in cell and developmental biology · 2026Article
- Electricity-Based Locoregional Cancer Therapies and Their Associated Drug Delivery Technologies: From Principles of Action to Clinical Implications.Biomaterials research · 2026Review
- Latest Advances and Ongoing Challenges in Pulsed Field Ablation.Arrhythmia & electrophysiology review · 2026Review
- Role of cell density and proximity in electroporation for tissue ablation.Communications physics · 2026Article
- Novel Combination of Irreversible Electroporation and Allogenic Chimeric Antigen Receptor T-Cell Therapy Synergizes Therapeutic Outcomes in a Preclinical Human Pancreatic Cancer Mouse Model.Research (Washington, D.C.) · 2026Article
- Uniform and Complete Irreversible Electroporation on Gastric Mucosa Enabled by Sintered Silver Hydrogel.Cyborg and bionic systems (Washington, D.C.) · 2026Article
- Article
- Mitigating muscle contractions during pulsed field ablation by utilizing intersegment delays.Bioelectrochemistry (Amsterdam, Netherlands) · 2025Article
- Invasive properties of patient-derived glioblastoma cells after reversible electroporationRadiology and oncology · 2025Article
- Characterization of glioma spheroid viability and metastatic potential following monophasic and biphasic pulsed electric fields.Bioelectrochemistry (Amsterdam, Netherlands) · 2025Article
- Article
- Effects of Interphase and Interpulse Delays on Tissue Impedance and Pulsed Field Ablation.Annals of biomedical engineering · 2025Article
- Focused ultrasound in modern medicine: bioengineering interfaces, molecular effects, and clinical breakthroughs.Frontiers in bioengineering and biotechnology · 2025Review
- Power-Driven Electroporation Is Predictive of Treatment Outcomes in a Conductivity-Independent Manner.BME frontiers · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundFocal ablation techniques are integral in the surgical intervention of diseased tissue, where it is necessary to minimize damage to the surrounding parenchyma and critical structures. Irreversible electroporation (IRE) and high-frequency IRE (H-FIRE), colloquially called pulsed-field ablation (PFA), utilize high-amplitude, low-energy pulsed electric fields (PEFs) to nonthermally ablate soft tissue. PEFs induce cell death through permeabilization of the cellular membrane, leading to loss of homeostasis. The unique nonthermal nature of PFA allows for selective cell death while minimally affecting surrounding proteinaceous structures, permitting treatment near sensitive anatomy where thermal ablation or surgical resection is contraindicated. Further, PFA is being used to treat tissue when tumor margins are not expected after surgical resection, termed margin accentuation. This review explores both the theoretical foundations of PFA, detailing how PEFs induce cell membrane destabilization and selective tissue ablation, the outcomes following treatment, and its clinical implications across oncology and cardiology.
conclusionsClinical experience is still progressing, but reports have demonstrated that PFA reduces complications often seen with thermal ablation techniques. Mounting oncology data also support that PFA produces a robust immune response that may prevent local recurrences and attenuate metastatic disease. Despite promising outcomes, challenges such as optimizing field delivery and addressing variations in tissue response require further investigation. Future directions include refining PFA protocols and expanding its application to other therapeutic areas like benign tissue hyperplasia and chronic bronchitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.